AXGN in Stage 2 Uptrend, Bull Flag near Highs with 7 of 8 Trend Checks

AXGN stock profile infographic with daily candles, 20, 50 and 150-day simple moving averages and volume, Stage 2 (Advancing), as of November 17, 2026 at 12:52 - CANSLIM Research
AXGN is trading at 55.38 in a confirmed Stage 2 advancing phase, holding above a rising 30-week moving average and passing 7 of 8 trend template checks. The stock has run 69.4 percent recently and is now forming a short bull flag just 5.5 percent off its 52-week high, with a pivot at 58.63 and no proper base yet given the one-week consolidation. Sentiment reads bullish at 6 out of 10, an offensive setup, though the missing relative-strength confirmation and volume still above average argue for patience until a breakout clears resistance.

AXGN   Daily · data to 2026-11-16 close · 20 SMA 50 SMA 150 SMA
Frozen at publication – this chart does not move. Open live chart on TradingView →

SECTORHealthcareINDUSTRYMedical DevicesStage 2Weinstein stage
Data to US close: Mon 16 Nov 16:00 ET = Tue 17 Nov 05:00 HKTCreated: Tue 17 Nov 12:52 HKT = 23:52 ET

Inside the Full Report

  • 🔒
    Stage AnalysisWhy the stock sits in this stage and what would change that
  • 🔒
    Detected PatternsWhich setups the scan found, with buy point and failure level
  • 🔒
    Trend Template: All 8 ChecksWhich criteria pass, which fail, and by how much
  • 🔒
    Fundamental SnapshotGrowth, margins, valuation and the earnings date


Disclaimer: This report is for informational and educational purposes only and does not constitute investment advice. Figures come from the scanned result (as of November 17, 2026) and company filings; all estimates not explicitly sourced from the provided data are clearly labeled as such. The analysis may contain errors — always verify against primary filings (10-K/10-Q/8-K) before making any investment decision.

About CANSLIM Research

CANSLIM Research is an independent project using AI to analyze global financial data by applying rule-based algorithms derived from well-known momentum traders. Our AI personas—simulations inspired by these methods with no trader affiliation or endorsement—scan stocks, analyze charts, track sector rotation, and publish educational insights under human oversight. Support via contributions, sponsorship, or partnership never buys stock-specific access, influences publishing, or involves paid security features. We are not a registered charity.

Disclaimer: All content is strictly educational—not investment advice, recommendations, or buy/sell solicitations. CANSLIM Research is not a licensed adviser or analyst under any regulatory body (including SEC, FINRA, SFC, FCA, SEBI, or EU authorities under ESMA). Investing carries risk of total loss, and past performance does not predict future results. Consult a licensed financial adviser before investing.